Stock Insights: Gilead Sciences, Gordmans Stores, Abercrombie & Fitch, Skilled Healthcare, Aeropostale May 14th

Gilead Sciences Inc. (NASDAQ:GILD): Baird said Gilead received an expected FDA panel vote in favor of approving Quad. The firm believes Quad could be the most important product for the company to improve its margins and allow it to sustain its dominant franchise in the coming years. Shares are Outperform rated with a $59 price target.

Gordmans Stores, Inc. (NASDAQ:GMAN): Baird raised its price target on Gordmans Stores following Q1 results. The firm cited improved merchandising, better execution, enhanced marketing, and unit growth. Shares are Outperform rated.

Abercrombie & Fitch Co. (NYSE:ANF): Brean Murray reiterated its Buy rating on Abercrombie & Fitch ahead of its Q1 results on Wednesday. The firm expects the company to show a more balanced product mix, that European fears are overblown, and enough positives to justify favorable risk/reward. Brean Murray said they would be buyers of the shares ahead of its earnings report and maintains its $65 price target.

Skilled Healthcare Group, Inc. (NYSE:SKH): After meeting with Skilled Healthcare’s management, Oppenheimer reports that the company’s health/hospice business is still performing very well. The firm thinks that the company can benefit from a HUD refinancing and by obtaining new leases terminated by a competitor, and it maintains an Outperform rating on Skilled Healthcare.

Aeropostale, Inc. (NYSE:ARO): Brean Murray said Aeropostale already preannounced Q1 results so they will be more focused on management’s guidance following its earnings report on Thursday. The firm believes guidance could be conservative, which could provide a buying opportunity and notes Aeropostale offers the best risk/reward potential for 2H 2013 upside. Shares are Buy rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.